Greylin Investment Mangement Inc. increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 47,685 shares of the biopharmaceutical company’s stock after purchasing an additional 600 shares during the quarter. Greylin Investment Mangement Inc.’s holdings in Pfizer were worth $1,713,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Evolution Wealth Advisors LLC acquired a new stake in Pfizer in the second quarter valued at $34,000. IMA Wealth Inc. lifted its holdings in Pfizer by 144.5% in the second quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 477 shares during the period. Financial Gravity Wealth Inc. lifted its holdings in Pfizer by 33.2% in the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 257 shares during the period. Vestor Capital LLC lifted its holdings in Pfizer by 60.1% in the second quarter. Vestor Capital LLC now owns 1,547 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 581 shares during the period. Finally, Global Trust Asset Management LLC lifted its holdings in Pfizer by 346.4% in the second quarter. Global Trust Asset Management LLC now owns 7,758 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 6,020 shares during the period. 71.69% of the stock is owned by hedge funds and other institutional investors.
Pfizer stock traded up $0.52 during midday trading on Friday, reaching $36.31. 10,877,390 shares of the company were exchanged, compared to its average volume of 19,407,336. The company has a market capitalization of $195.97 billion, a price-to-earnings ratio of 12.10, a P/E/G ratio of 2.82 and a beta of 0.66. The firm’s 50-day simple moving average is $35.94 and its 200-day simple moving average is $39.97. Pfizer Inc. has a 1 year low of $33.97 and a 1 year high of $46.47. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.05. The firm had revenue of $13.26 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The firm’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.77 EPS. On average, analysts forecast that Pfizer Inc. will post 2.81 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 3.97%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio is presently 48.00%.
A number of research firms have commented on PFE. Bank of America downgraded Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. UBS Group reaffirmed a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research note on Monday, August 5th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a research note on Monday, August 12th. Morgan Stanley cut their price target on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 27th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $49.00 price target on shares of Pfizer in a research note on Monday, June 17th. Twelve analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $45.20.
In related news, Director Scott Gottlieb acquired 3,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the transaction, the director now owns 3,000 shares in the company, valued at approximately $104,160. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Pfizer Inc acquired 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: Marijuana Stocks
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.